dc.contributor.author |
Gening S.O. |
|
dc.contributor.author |
Abakumova T.V. |
|
dc.contributor.author |
Gafurbaeva D.U. |
|
dc.contributor.author |
Rizvanov A.A. |
|
dc.contributor.author |
Antoneeva I.I. |
|
dc.contributor.author |
Miftakhova R.R. |
|
dc.contributor.author |
Peskov A.B. |
|
dc.contributor.author |
Gening T.P. |
|
dc.date.accessioned |
2022-02-09T20:44:01Z |
|
dc.date.available |
2022-02-09T20:44:01Z |
|
dc.date.issued |
2021 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/169897 |
|
dc.description.abstract |
Stem properties allow circulating tumor cells (CTCs) to survive in the bloodstream and initiate cancer progression. We aimed to assess the numbers of stem-like CTCs in patients with ovarian cancer (OC) before treatment and during first-line chemotherapy (CT). Flow cytometry was performed (Cytoflex S (Beckman Coulter, CA, USA)) using antibodies against CD45; epithelial markers EpCAM and cytokeratin (CK) 8,18; mesenchymal vimentin (vim); and stem-like CD44, CD133 and ALDH. This study included 38 stage I–IV OC patients (median age 66 (Q1–Q3 53–70)). The CK+vim-counts were higher (p = 0.012) and the CD133+ALDHhigh counts were lower (p = 0.010) before treatment in the neoadjuvant CT group than in the adjuvant group. The patients with ascites had more CK+vim-cells before treatment (p = 0.009) and less EpCAM-vim+ cells during treatment (p = 0.018) than the patients without ascites. All the CTC counts did not differ significantly in paired samples. Correlations were found between the CK-vim+ and CD133+ALDHhigh (r = 0.505, p = 0.027) and EpCAM-vim+ and ALDHhigh (r = 0.597, p = 0.004) cells before but not during treatment. Multivariate Cox regression analysis showed that progression-free survival was longer with the presence of surgical treatment (HR 0.06 95% CI 0.01–0.48, p = 0.009) and fewer CD133+ALDHveryhigh cells (HR 1.06 95% CI 1.02–1.12, p = 0.010). Thus, CD133+ALDH+ CTCs have the greatest prognostic potential in OC among the phenotypes studied. |
|
dc.subject |
ALDH |
|
dc.subject |
CD133 |
|
dc.subject |
CD44 |
|
dc.subject |
Circulating tumor cells |
|
dc.subject |
CTCs |
|
dc.subject |
Cytokeratin |
|
dc.subject |
EpCAM |
|
dc.subject |
Ovarian cancer |
|
dc.subject |
Stem cells |
|
dc.subject |
Vimentin |
|
dc.title |
The detection of stem-like circulating tumor cells could increase the clinical applicability of liquid biopsy in ovarian cancer |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
8 |
|
dc.relation.ispartofseries-volume |
11 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.source.id |
SCOPUS-2021-11-8-SID85113170662 |
|